SCHEMBL5547422

SCHEMBL5547422

C=CNc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
CYP2A6 P11509 1/20 0.42
MAPT P10636 7/20 0.39
HTT P42858 5/20 0.39
TSHR P16473 1/20 0.39
NLRP3 Q96P20 1/20 0.39
NPC1 O15118 4/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 4/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
CES1 P23141 1/20 0.37
GAA P10253 2/20 0.37
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NLRP1 Q9C000 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153234 0.86 ALDH1A1 (0.35) LMNAALDH1A1
SCHEMBL183037 0.74 ALDH1A1 (0.56) LMNACYP2A6MAPTHTTTSHR
SCHEMBL3090718 0.74 CA1 (0.43) LMNACYP2A6MAPTHTTNPC1
SCHEMBL28015144 0.74 LMNA (0.42) LMNACYP2A6MAPTHTTTSHR
SCHEMBL4525438 0.74 TSHR (0.43) LMNACYP2A6MAPTHTTTSHR
SCHEMBL23513176 0.74 TGM2 (0.48) LMNAMAPTHTTTSHRNPC1
SCHEMBL9271544 0.74 MAPT (0.42) LMNAMAPTHTTCA1CA2
SCHEMBL14471113 0.74 APP (0.44) MAPTTSHRCA1CA2ALDH1A1
SCHEMBL1485943 0.74 TGM2 (0.48) LMNACYP2A6MAPTHTTNPC1
SCHEMBL27642601 0.74 TGM2 (0.48) LMNACYP2A6MAPTTSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107118145-A A kind of method of the Cyclization indoles of palladium organic nitroso hydrochlorate co-catalysis 中国科学技术大学 2017-09-01 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885CYP2A6 1119/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.